Shares of PharMerica Corp. (NYSE:PMC) saw unusually-high trading volume on Friday . Approximately 265,702 shares changed hands during trading, an increase of 80% from the previous session’s volume of 147,530 shares.The stock last traded at $26.54 and had previously closed at $26.31.

PMC has been the subject of several analyst reports. Bank of America Corp. initiated coverage on shares of PharMerica Corp. in a research report on Tuesday, June 7th. They set a “buy” rating and a $32.00 price target for the company. Zacks Investment Research downgraded shares of PharMerica Corp. from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 13th. TheStreet downgraded shares of PharMerica Corp. from a “buy” rating to a “hold” rating in a research report on Monday, May 9th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $34.00 target price (up previously from $30.00) on shares of PharMerica Corp. in a research report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $31.57.

The stock’s 50 day moving average price is $25.39 and its 200 day moving average price is $25.41. The firm has a market capitalization of $816.30 million and a PE ratio of 27.67.

PharMerica Corp. (NYSE:PMC) last posted its earnings results on Friday, May 6th. The company reported $0.45 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.02. The firm had revenue of $524.50 million for the quarter, compared to analysts’ expectations of $509.45 million. The company’s revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.48 EPS. On average, analysts forecast that PharMerica Corp. will post $2.02 earnings per share for the current year.

Other large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in PharMerica Corp. by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,579,111 shares of the company’s stock worth $90,269,000 after buying an additional 41,387 shares during the last quarter. Airain ltd boosted its stake in PharMerica Corp. by 8,998.1% in the fourth quarter. Airain ltd now owns 1,222,061 shares of the company’s stock worth $14,499,000 after buying an additional 1,208,629 shares during the last quarter. Bank of Montreal Can boosted its stake in PharMerica Corp. by 41.2% in the fourth quarter. Bank of Montreal Can now owns 563,528 shares of the company’s stock worth $19,724,000 after buying an additional 164,443 shares during the last quarter. Systematic Financial Management LP boosted its stake in PharMerica Corp. by 12.0% in the fourth quarter. Systematic Financial Management LP now owns 486,036 shares of the company’s stock worth $17,011,000 after buying an additional 51,887 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in PharMerica Corp. by 3.6% in the fourth quarter. Wells Fargo & Company MN now owns 305,474 shares of the company’s stock worth $10,692,000 after buying an additional 10,609 shares during the last quarter.

PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.